AIM ImmunoTech has submitted a pre-investigational new drug (Pre-IND) application to the US Food and Drug Administration (FDA) for a study of Ampligen as a potential infusion treatment for post-Covid-19 cognitive dysfunction (PCCD).
The Drugs Controller General of India (DCGI) has given approval to Reliance Life Sciences to conduct a Phase I clinical trial of its Covid-19 vaccine with certain conditions.
Senhwa Biosciences has announced that its oral drug, Silmitasertib, has received positive feedback from an independent Data Monitoring Committee (DMC) in an interim review of Phase II investigator-initiated trial in patients with severe Covid-19.
Moderna has announced that in a new study its Covid-19 messenger ribonucleic acid (mRNA) vaccine showed durable efficacy in generating neutralising antibodies against SARS-CoV-2 variants of concern.
Inovio has secured approval from Center for Drug Evaluation of the National Medical Products Administration in China to carry out two clinical trials of heterologous prime-boosting with its Covid-19 vaccine candidate, INO-4800.
India has given approval to Johnson & Johnson’s (J&J) single-dose Covid-19 vaccine for emergency use.
Akston Biosciences has initiated dosing of the first subjects in a Phase II open-label trial of AKS-452, its protein subunit Covid-19 vaccine candidate.
Brii Biosciences has announced that ACTIV-2 clinical trial of the National Institutes of Health (NIH) in the US closed enrolment for the Phase III part that will evaluate BRII-196 plus BRII-198 for Covid-19 treatment.
Dr. Reddy’s Laboratories has started a limited pilot of the Sputnik V Covid-19 vaccine, developed by Russian scientists, in India following regulatory authorisation from the Central Drugs Laboratory.
The US Food and Drug Administration (FDA) has expanded the emergency use authorisation (EUA) for Pfizer and BioNTech’s Covid-19 vaccine to include adolescents aged 12 to 15 years.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.